Diagnostic potential of serum exosomal colorectal neoplasia differentially expressed long non-coding RNA (CRNDE-p) and microRNA-217 expression in colorectal carcinoma.

Bo Yu,Huan Li,Xuan Ye,Hong-Yue Liu,Xin-Xiang Li,Qing Zhai,Bin Zhu,Qiong Du

doi:10.18632/oncotarget.19407

Abstract

In this study, we investigated the diagnostic potential of serum exosomal colorectal neoplasia differentially expressed (CRNDE-p) long coding RNA and microRNA-217 in colorectal carcinoma (CRC). We detected high CRNDE-p and low miR-217 levels in exosomes released by multiple CRC cell lines into culture media as well as in sera from CRC xenograft mice and CRC patients. Conversely, we observed lower CRNDE-p and higher miR-217 levels in serum exosomes from post-chemotherapy than from pre-chemotherapy patient samples. The area under curve (AUC) value for the serum exosomal CRNDE-p and miR-217 combination was higher than CRNDE-p or miR-217 alone. Moreover, high CRNDE-p and low miR-217 serum exosomal levels correlated with advanced clinical stages (III/IV), tumor classification (T3/T4), and lymph node or distant metastasis. Thus combined evaluation of serum exosomal CRNDE-p and miR-217 levels show diagnostic and prognostic potential for CRC patients.

Highlights

Colorectal carcinoma (CRC) is one of the main causes of cancer mortality worldwide, accounting for 15% of all newly diagnosed cancers
We investigated the diagnostic potential of serum exosomal colorectal neoplasia differentially expressed (CRNDE-p) long coding RNA and microRNA-217 in colorectal carcinoma (CRC)
We observed high CRNDE-p and low miR-217 levels in exosomes released from CRC cells than in exosomes released from the control NCM460 cells by quantitative real-time-PCR (Figure 2A) and Northern blot (Figure 2B)

Summary

Introduction

Colorectal carcinoma (CRC) is one of the main causes of cancer mortality worldwide, accounting for 15% of all newly diagnosed cancers. The median age of newly diagnosed patients is between 60 and 80 years of age [1,2,3]. Diagnosis and treatment significantly improves the overall survival rate of CRC patients [4, 5]. Colonoscopy provides the highest diagnostic accuracy, but is inconvenient and invasive and limited in its use for preliminary diagnosis. Plasma and serum biomarkers are critical for CRC diagnosis [6,7,8]. The preferred biomarker is carcinoembryonic antigen (CEA), which exhibits low sensitivity and specificity in the early stages of CRC. New CRC-specific biomarkers are urgently required to complement and improve the current CRC diagnostic strategies

Methods

Results

Conclusion